Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.38 USD | +2.99% |
|
+2.99% | -47.33% |
May. 09 | Transcript : Apyx Medical Corporation, Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Stavros Vizirgianakis Enters into Letter Agreement with Apyx Medical | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-47.33% | 47.81M | C | ||
-5.50% | 181B | C+ | ||
-5.79% | 99.52B | C | ||
-6.59% | 65.82B | A | ||
-8.38% | 45.21B | B- | ||
+8.42% | 43.85B | B- | ||
+10.10% | 42.17B | B+ | ||
+10.97% | 28.75B | B | ||
+18.89% | 25.39B | A- | ||
-8.39% | 23.5B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- APYX Stock
- Ratings Apyx Medical Corporation